SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Gaskin Gill)
 

Search: WFRF:(Gaskin Gill) > (2005-2009) > Randomized trial of...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Jayne, David R. W. (author)

Randomized trial of plasma exchange or high-dosage Methylprednisolone as adjunctive therapy for severe renal vasculitis

  • Article/chapterEnglish2007

Publisher, publication year, extent ...

  • 2007

Numbers

  • LIBRIS-ID:oai:lup.lub.lu.se:0c18d0a7-6fb1-4429-aeb2-f79fd936e46a
  • https://lup.lub.lu.se/record/691595URI
  • https://doi.org/10.1681/ASN.2007010090DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:art swepub-publicationtype
  • Subject category:ref swepub-contenttype

Notes

  • Systemic vasculitis associated with autoantibodies to neutrophil cytoplasmic antigens (ANCA) is the most frequent cause of rapidly progressive glomerulonephritis. Renal failure at presentation carries an increased risk for ESRD and death despite immunosuppressive therapy. This study investigated whether the addition of plasma exchange was more effective than intravenous methylprednisolone in the achievement of renal recovery in those who presented with a serum creatinine > 500 mu mol/L (5.8 mg/dl). A total of 137 patients with a new diagnosis of ANCA-associated systemic vasculitis confirmed by renal biopsy and serum creatinine > 500 mu mol/L (5.8 mg/dl) were randomly assigned to receive seven plasma exchanges (n = 70) or 3000 mg of intravenous methylprednisolone (n = 67). Both groups received oral cyclophosphamide and oral prednisolone. The primary end point was dialysis independence at 3 mo. Secondary end points included renal and patient survival at 1 yr and severe adverse event rates. At 3 mo, 33 (49%) of 67 after intravenous methylprednisolone compared with 48 (69%) or 70 after plasma exchange were alive and independent of dialysis (95% confidence interval for the difference 18 to 35%; P = 0.02). As compared with intravenous methylprednisolone, plasma exchange was associated with a reduction in risk for progression to ESRD of 24% (95% confidence interval 6.1 to 41%), from 43 to 19%, at 12 mo. Patient survival and severe adverse event rates at 1 yr were 51 (76%) of 67 and 32 of 67 (48%) in the intravenous methylprednisolone group and 51 (73%) of 70 and 35 of (50%) 70 in the plasma exchange group, respectively. Plasma exchange increased the rate of renal recovery in ANCA-associated systemic vasculitis that presented with renal failure when compared with intravenous methylprednisolone. Patient survival and severe adverse event rates were similar in both groups.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Gaskin, Gill (author)
  • Rasmussen, Niels (author)
  • Abramowicz, Daniel (author)
  • Ferrario, Franco (author)
  • Guillevin, Loic (author)
  • Mirapeix, Eduardo (author)
  • Savage, Caroline O. S. (author)
  • Sinico, Renato A. (author)
  • Stegeman, Coen A. (author)
  • Westman, KerstinLund University,Lunds universitet,Njurmedicin,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Nephrology,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine(Swepub:lu)njur-kwe (author)
  • van der Woude, Fokko J. (author)
  • van Wijngaarden, Robert A. F. de Lind (author)
  • Pusey, Charles D. (author)
  • NjurmedicinSektion II (creator_code:org_t)

Related titles

  • In:Journal of the American Society of Nephrology18:7, s. 2180-21881046-6673

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view